Grisham et al. demonstrated that the presence of BRAF mutations in serous borderline ovarian tumor or low-grade serous ovarian carcinoma was relevant to early-stage disease and favorable prognoses [21]. The gene discussed is BRAF; the disease is ovarian serous carcinoma.